+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Osimertinib Mesylate Tablets Market - Global Forecast 2026-2032- Product Image
Osimertinib Mesylate Tablets Market - Global Forecast 2026-2032- Product Image
Sale

Osimertinib Mesylate Tablets Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6135129
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Osimertinib Mesylate Tablets Market is projected to reach USD 6.66 Billion in 2026. It is expected to continue growing at a CAGR of 13.04%, reaching USD 13.88 Billion by 2032.

Osimertinib Mesylate Tablets: Executive Summary

Osimertinib mesylate tablets are an oral targeted therapy used primarily in the treatment of non-small cell lung cancer with specific epidermal growth factor receptor (EGFR) mutations. Their clinical role is shaped by biomarker testing, treatment-line guidance, regulatory indications, safety monitoring, and access to oncology services. This summary reviews the forces influencing use across major regions, country groups, and selected countries without presenting market estimates or forecasts.

Biomarker-Led Care Is Reshaping Treatment Pathways

The treatment landscape is moving toward biomarker-led diagnosis and therapy selection. EGFR mutation testing, including assessment for sensitizing mutations and acquired resistance mechanisms, is central to determining eligibility and managing progression. Liquid biopsy can complement tissue testing when tissue is limited, while multidisciplinary care increasingly combines radiology, pathology, molecular diagnostics, oncology, and patient-support services. Access remains influenced by diagnostic turnaround times, reimbursement rules, treatment guidelines, and the capacity to monitor adverse effects such as interstitial lung disease, QT-interval prolongation, cardiomyopathy, and diarrhea.

Artificial Intelligence Strengthens Precision Oncology Workflows

Artificial intelligence can support radiology review, pathology interpretation, molecular testing workflows, clinical-trial matching, adverse-event surveillance, and identification of patients who may need follow-up. Its practical value depends on representative training data, transparent validation, interoperability with electronic health records, and clinician oversight. AI should complement-not replace-confirmatory laboratory testing, medical judgment, informed consent, and established pharmacovigilance processes. Governance is particularly important where algorithms influence treatment selection or prioritize scarce diagnostic resources.

Regional Differences Reflect Diagnosis, Regulation, and Access

North America generally benefits from advanced oncology infrastructure and established molecular-testing pathways, while access and reimbursement can differ by jurisdiction and payer. Europe combines extensive clinical-guideline development with variation among national health systems, health-technology assessments, and procurement processes. Asia-Pacific contains highly developed oncology centers alongside settings where testing and specialist capacity remain uneven. Latin America faces differences in public and private coverage, diagnostic availability, and treatment affordability. The Middle East is expanding specialized cancer services but shows variation in national coverage and referral capacity. Africa continues to face major challenges involving molecular diagnostics, oncology workforce availability, medicine procurement, and continuity of care; regional partnerships and decentralized testing may help address these gaps.

International Groupings Reveal Shared Policy Priorities

ASEAN members have an opportunity to improve cross-border oncology capacity through harmonized diagnostic standards, training, and procurement collaboration. BRICS countries represent diverse health-system models and can share experience in local manufacturing, clinical research, and access programs while maintaining rigorous quality controls. The European Union emphasizes coordinated scientific and regulatory standards, although national reimbursement decisions remain distinct. G7 health systems generally have strong research and pharmacovigilance capabilities but continue to address affordability, workforce pressures, and equitable access. GCC states are investing in specialized healthcare infrastructure and can strengthen regional referral and genomic-testing networks. NATO members span different health systems, yet cooperation on resilience, supply continuity, and emergency preparedness is relevant to oncology medicine access.

Country-Level Priorities Differ Across Established and Emerging Systems

Australia and Canada have publicly oriented health systems in which reimbursement decisions, diagnostic access, and specialist capacity influence treatment availability. Brazil and Mexico face variation between public and private oncology services and may benefit from stronger molecular-testing coverage. China is expanding precision-oncology capabilities while navigating regulatory, procurement, and regional-access differences. India combines major tertiary-care expertise with substantial variation in affordability, testing, and rural access. Japan and South Korea have sophisticated oncology ecosystems with continued attention to guideline implementation, safety monitoring, and demographic pressures. In Europe, France, Germany, Italy, Spain, and the United Kingdom apply mature regulatory and clinical infrastructures, but reimbursement pathways, health-technology assessment, and regional service organization differ. Russia’s access environment is shaped by national procurement, domestic supply considerations, specialist availability, and continuity of diagnostic services. In the United States, broad clinical research capacity and molecular testing coexist with payer variation, prior authorization, and disparities in access.

Industry Leaders Should Prioritize Evidence, Access, and Safety

Leaders should align clinical development and medical education with validated EGFR testing, clearly defined patient populations, and outcomes that matter to clinicians and patients. They should strengthen partnerships with laboratories and healthcare systems to improve test availability, reporting quality, and turnaround time. Robust pharmacovigilance should include practical protocols for pulmonary, cardiac, gastrointestinal, and ocular monitoring, supported by clear patient education. Supply planning should address quality assurance, continuity, local regulatory requirements, and equitable distribution. Finally, organizations should use AI selectively, with documented validation, privacy safeguards, bias monitoring, and clinician accountability.

Methodology: Evidence-Based Review of Clinical and Health-System Drivers

This executive summary uses a qualitative synthesis framework focused on the therapeutic role of osimertinib mesylate tablets, EGFR-directed treatment pathways, diagnostic requirements, safety considerations, regulatory and reimbursement conditions, and differences in healthcare-system capacity. Regional, group, and country narratives are comparative rather than quantitative. Claims should be checked against current regulatory labeling, peer-reviewed clinical evidence, professional guidelines, health-technology assessments, pharmacovigilance communications, and official national policy sources before operational or clinical decisions are made.

Conclusion: Precision-Medicine Infrastructure Will Shape Adoption

The position of osimertinib mesylate tablets in oncology is closely tied to accurate EGFR identification, appropriate sequencing, patient monitoring, and reliable access to specialist care. The most consequential differences across regions and countries arise from diagnostic infrastructure, reimbursement, regulatory practice, supply continuity, and health-system capacity. Sustainable progress will depend on integrating molecular diagnostics with evidence-based treatment, strengthening safety oversight, and applying digital and AI tools responsibly.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Osimertinib Mesylate Tablets Market, by Manufacturer Type
7.1. Introduction
7.2. Branded
7.3. Generic
8. Osimertinib Mesylate Tablets Market, by Indication
8.1. Introduction
8.2. First Line Non-Small-Cell Lung Cancer
8.3. Metastatic Non-Small-Cell Lung Cancer
8.3.1. Egfr Sensitizing Mutation
8.3.2. Egfr T790M Positive
8.4. Second Line Non-Small-Cell Lung Cancer
9. Osimertinib Mesylate Tablets Market, by Dosage Strength
9.1. Introduction
9.2. 40 Mg
9.3. 80 Mg
10. Osimertinib Mesylate Tablets Market, by End User
10.1. Introduction
10.2. Ambulatory Care Center
10.3. Hospital
10.4. Specialty Clinic
11. Osimertinib Mesylate Tablets Market, by Distribution Channel
11.1. Introduction
11.2. Offline Pharmacy
11.3. Online Pharmacy
12. Osimertinib Mesylate Tablets Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Osimertinib Mesylate Tablets Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Osimertinib Mesylate Tablets Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alembic Pharmaceuticals Limited
16.2. Alkem Laboratories Limited
16.3. Anax Pharma Private Limited
16.4. Aristo Pharmaceuticals Private Limited
16.5. AstraZeneca PLC
16.6. Aurobindo Pharma Limited
16.7. Beacon Pharmaceuticals Limited
16.8. Bulat Pharmaceutical Private Limited
16.9. Cipla Limited
16.10. Dr. Reddy’s Laboratories Limited
16.11. Drug International Limited
16.12. Everest Organics Limited
16.13. General Pharmaceuticals Limited
16.14. Hetero Drugs Limited
16.15. Hexacare Pharmaceuticals Private Limited
16.16. Intas Pharmaceuticals Limited
16.17. Natco Pharma Limited
16.18. Viatris Inc.
16.19. Wanbang Biopharmaceuticals Group Co., Ltd.
16.20. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Osimertinib Mesylate Tablets Market, Years Considered for the Study
FIGURE 2. Global Osimertinib Mesylate Tablets Market, Research Design
FIGURE 3. Global Osimertinib Mesylate Tablets Market, Research Framework
FIGURE 4. Global Osimertinib Mesylate Tablets Market, Data Triangulation
FIGURE 5. Global Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2025 vs 2032 (%)
FIGURE 7. Global Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Osimertinib Mesylate Tablets Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Osimertinib Mesylate Tablets Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 11. Global Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Osimertinib Mesylate Tablets Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Osimertinib Mesylate Tablets Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Osimertinib Mesylate Tablets Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Osimertinib Mesylate Tablets Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Osimertinib Mesylate Tablets Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Osimertinib Mesylate Tablets Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Osimertinib Mesylate Tablets Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Osimertinib Mesylate Tablets Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Osimertinib Mesylate Tablets Market Segmentation & Coverage
TABLE 2. Global Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 3. Global Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 4. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 11. Global First Line Non-Small-Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global First Line Non-Small-Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global First Line Non-Small-Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Metastatic Non-Small-Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Metastatic Non-Small-Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Metastatic Non-Small-Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Egfr Sensitizing Mutation Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Egfr Sensitizing Mutation Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Egfr Sensitizing Mutation Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Egfr T790M Positive Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Egfr T790M Positive Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Egfr T790M Positive Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Second Line Non-Small-Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Second Line Non-Small-Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Second Line Non-Small-Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 27. Global 40 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global 40 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global 40 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global 80 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global 80 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global 80 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 34. Global Ambulatory Care Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ambulatory Care Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ambulatory Care Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 44. Global Offline Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Offline Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Offline Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 58. North America Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. North America Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 60. North America Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 61. North America Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 62. North America Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 63. North America Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 64. North America Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 65. Latin America Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Latin America Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 67. Latin America Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 68. Latin America Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 69. Latin America Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 70. Latin America Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Latin America Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Europe Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Europe Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 74. Europe Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 75. Europe Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 76. Europe Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 77. Europe Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Europe Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 79. Middle East Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Middle East Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 81. Middle East Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 82. Middle East Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 83. Middle East Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 84. Middle East Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Middle East Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Africa Osimertinib Mesylate Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Africa Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 88. Africa Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 89. Africa Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 90. Africa Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 91. Africa Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Africa Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Global Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. ASEAN Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. ASEAN Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 96. ASEAN Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. ASEAN Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 98. ASEAN Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 99. ASEAN Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 100. ASEAN Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. GCC Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. GCC Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 103. GCC Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. GCC Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 105. GCC Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 106. GCC Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. GCC Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. European Union Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. European Union Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 110. European Union Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 111. European Union Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 112. European Union Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 113. European Union Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. European Union Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. BRICS Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. BRICS Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 117. BRICS Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 118. BRICS Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 119. BRICS Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 120. BRICS Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. BRICS Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. G7 Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. G7 Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 124. G7 Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 125. G7 Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 126. G7 Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 127. G7 Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. G7 Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. NATO Osimertinib Mesylate Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. NATO Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 131. NATO Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. NATO Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 133. NATO Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 134. NATO Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. NATO Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Global Osimertinib Mesylate Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. United States Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 138. United States Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 139. United States Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. United States Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 141. United States Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 142. United States Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. United States Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. Canada Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 145. Canada Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 146. Canada Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. Canada Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 148. Canada Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 149. Canada Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Canada Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. Mexico Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 152. Mexico Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 153. Mexico Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 154. Mexico Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 155. Mexico Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 156. Mexico Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Mexico Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. Brazil Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 159. Brazil Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 160. Brazil Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. Brazil Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 162. Brazil Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 163. Brazil Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. Brazil Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. United Kingdom Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 166. United Kingdom Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 167. United Kingdom Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. United Kingdom Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 169. United Kingdom Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 170. United Kingdom Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. United Kingdom Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. Germany Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 173. Germany Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 174. Germany Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 175. Germany Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 176. Germany Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 177. Germany Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Germany Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. France Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 180. France Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 181. France Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 182. France Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 183. France Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 184. France Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. France Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Russia Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 187. Russia Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 188. Russia Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. Russia Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 190. Russia Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 191. Russia Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. Russia Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. Italy Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 194. Italy Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 195. Italy Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. Italy Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 197. Italy Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 198. Italy Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Italy Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Spain Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 201. Spain Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 202. Spain Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. Spain Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 204. Spain Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 205. Spain Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Spain Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. China Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 208. China Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 209. China Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 210. China Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 211. China Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 212. China Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. China Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. India Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 215. India Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 216. India Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 217. India Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 218. India Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 219. India Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. India Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. Japan Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 222. Japan Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 223. Japan Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. Japan Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 225. Japan Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 226. Japan Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Japan Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. Australia Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 229. Australia Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 230. Australia Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. Australia Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 232. Australia Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 233. Australia Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. Australia Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 235. South Korea Osimertinib Mesylate Tablets Market Size, 2017-2032 (USD Million)
TABLE 236. South Korea Osimertinib Mesylate Tablets Market Size, by Manufacturer Type, 2017-2032 (USD Million)
TABLE 237. South Korea Osimertinib Mesylate Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 238. South Korea Osimertinib Mesylate Tablets Market Size, by Metastatic Non-Small-Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 239. South Korea Osimertinib Mesylate Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 240. South Korea Osimertinib Mesylate Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. South Korea Osimertinib Mesylate Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. Global Osimertinib Mesylate Tablets Market Share, by Key Player, 2025
TABLE 243. Global Osimertinib Mesylate Tablets Market, Key Experts

Companies Mentioned

  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Anax Pharma Private Limited
  • Aristo Pharmaceuticals Private Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Beacon Pharmaceuticals Limited
  • Bulat Pharmaceutical Private Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Drug International Limited
  • Everest Organics Limited
  • General Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Hexacare Pharmaceuticals Private Limited
  • Intas Pharmaceuticals Limited
  • Natco Pharma Limited
  • Viatris Inc.
  • Wanbang Biopharmaceuticals Group Co., Ltd.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Enzalutamide Tablets Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Tablets Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Sotorasib Tablets Market Report 2026 - Product Image

Sotorasib Tablets Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Tucatinib Tablets Market - Global Forecast 2026-2032 - Product Image

Tucatinib Tablets Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Isosorbide Mononitrate Tablet Market Report 2026 - Product Image

Isosorbide Mononitrate Tablet Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Xuesaitong Tablet Market Report: Trends, Forecast and Competitive Analysis to 2035 - Product Image

Xuesaitong Tablet Market Report: Trends, Forecast and Competitive Analysis to 2035

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.